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ABSTRACT  
Paracetamol, a frequently used antipyretic and analgesic drug, has poor compression moldability 
owing to its low plasticity. In this study, new co-crystals of paracetamol (PCM) with caffeine (as a 
co-former) were prepared and delineated. Co-crystals exhibited improved compaction and 
mechanical behavior. A screening study was performed by utilizing a number of methods namely 
dry grinding, liquid assisted grinding (LAG), solvent evaporation (SE) and anti-solvent addition 
using various weight ratios of starting materials. LAG and SE were found successful in the 
screening study. Powders at 1:1 and 2:1 weight ratio of PCM/CAF by LAG and SE respectively 
resulted in the formation of co-crystals. Samples were characterized by PXRD, DSC and ATR-
FTIR techniques. Compressional properties of PCM and developed co-crystals were analyzed by 
in-die heckle model. Mean yield pressure (Py), an inverse measure of plasticity, obtained from the 
heckle plots decreased significantly (p<0.05) for co-crystals than pure drug. Intrinsic dissolution 
profile of co-crystals showed up to 2.84 fold faster dissolution than PCM and physical mixtures in 
phosphate buffer pH 6.8 at 37 oC. In addition co-crystals formulated into tablets by direct 
compression method showed better mechanical properties like hardness and tensile strength. In 
vitro dissolution studies on tablets also showed enhanced dissolution profiles (~90- 97%) in 
comparison to the tablets of PCM prepared by direct compression (~55%) and wet granulation 
(~85%) methods. In a single dose sheep model study co-crystals showed up to two fold increase in 
AUC and Cmax. A significant (p < 0.05) decrease in clearance as compared to pure drug was also 
recorded. In conclusion new co-crystals of PCM were successfully prepared with improved 
tabletability in-vitro and in-vivo profile. Enhancement in AUC and Cmax of PCM by co-
crystallisation might suggest the dose reduction and avoidance of side effects. 
Key Words: Paracetamol, Caffeine, Co-crystals, Intrinsic dissolution rate, Tabletability, In-vitro 
dissolution, Bioavailability 
INTRODUCTION 
The successful development of a pharmaceutical dosage form requires adequate physical and 
mechanical properties of an active pharmaceutical ingredient (API). However, APIs with limited 
physical properties are becoming prevalent during the research and development process in 
pharmaceutical companies. Some compounds have less aqueous solubility and slow in vivo 
dissolution rate especially those belonging to the BCS class II (Low solubility and high 
permeability) and IV (Low solubility and low permeability) (1-4) others have high hygroscopicity 
and exhibit poor compaction properties. The properties e.g. solubility and dissolution rate are 
directly related to the bioavailability of the drugs, particularly when delivered via oral route (5, 6). 
On the other hand poor mechanical properties cause difficulties in the processing e.g. milling and 
compaction of a solid dosage form. Advancement in the pharmaceutical sciences has resulted in 
the establishment of a number of approaches to address these issues. These approaches include 
reduction of particle size (7), salt formation (8), prodrug formation, complexation (9, 10) and 
liposomes for the delivery of lipophilic drugs (11). Although these techniques are very effective 
in enhancing the oral bioavailability and processing properties of drugs, the success of these 
approaches is dependent on the specific physicochemical nature of the compound being studied. 
For example salt formation which is only limited to ionizable compounds, complexation with 
disadvantages like low extent of interaction with complexing agent, increased toxicity, high cost 
and precipitation, prodrug which may not be adequately delivered at the site of action and particle 
size reduction limited by particle size induction and amorphization. 
In recent years advancement in crystal engineering techniques like co-crystallization provides an 
alternative approach for improving various physicochemical properties of drug substances (12-
15). Control of molecular packing within a crystal structure/lattice produces a solid that shows 
desirable characteristics including chemical stability (16, 17, 18), solid state stability (19), 
dissolution rate and bioavailability (20, 21), and compaction behavior (22-24). Furthermore, co-
crystals may have an advantage over the high-energy crystal forms of superior thermodynamic 
stability in the solid-state (6, 25). Therefore the interest in the co-crystallization has increased 
considerably over the past few years.  
Pharmaceutical co-crystals are defined as supramolecular entities consisting of two or more 
molecular moieties held together by weak non-covalent and non-ionic intermolecular interactions 
(e.g. hydrogen bonding, p stacking, and VanderWaals forces) in which at least one or both 
constituents are active pharmaceutical agents i.e. two different molecules in a single crystalline 
lattice (26, 27). Drugs having the ability to form hydrogen bonding with co-formers are considered 
as potential candidates for co-crystallization technique. Co-crystals of many pharmaceutical drugs 
are reported in literature e.g. carbamazepine, indomethacin, furosemide and piroxicam etc. (28). 
Recently various novel methods for the efficient production and monitoring of co-crystals have 
been proposed (29). 
Paracetamol (PCM) is widely used analgesic and antipyretic agent. It has low aqueous solubility 
and poor mechanical and compressional properties and hence has poor tabletability. Many studies 
have reported the problem of high capping which is related to stiff nature and a relatively high 
elastic deformation of PCM (30). Due to these reasons, PCM tablets are being prepared using large 
amount of a binder to prevent chipping and disintegration of tablet dosage form (24). Similarly a 
change in crystal structure e.g. polymorphsim or crystal habit has been shown to improve tableting 
properties of PCM (31). Nevertheless lack of acidic or basic functional groups and presence of 
both proton donors (phenolic O-H and the amidic N-H groups) and acceptor (the amidic oxygen 
atom) make PCM a good model drug for co-crystal study. Caffeine (CAF) has already been 
successfully utilized as a co-former, and is a generally recognized as safe (GRAS) status 
compound. It has functional groups (keto-amide groups and basic nitrogen) which make it as a 
good candidate to form intermolecular hydrogen bonds in co-crystal formation (Figure 1) (22). 
Furthermore PCM is also available as fixed dose combination with caffeine to synergise the 
analgesic effect of PCM. 
In the present work attempts were made to produce co-crystals of PCM with CAF as a co-former, 
these co-crystals has not been reported previously. Four different co-crystallisation methods were 
employed in the screening studies, with the aim to improve the compressional, mechanical 
behaviour and dissolution profile of the drug. Prepared co-crystals were evaluated for intrinsic 
dissolution rate and compaction behavior. Previously mechanical properties of co-crystals were 
determined by measuring the tensile strength only, however our study involves the heckle analysis, 
which give more thorough insight about the plasticity. Pharmacokinetic studies of newly formed 
co-crystals were also performed on sheep model in order to highlight the potential increase in oral 
bioavailability. Literature review has shown that only a few bioavailability studies have been 
reported for the co-crystals (19, 20). To our knowledge, this is the first bioavailability study done 
one the PCM co-crystals. Lastly tablet formulations prepared from these co-crystals were also 
assessed for the pharmacotechnical properties.  
Place figure 1 here 
EXPERIMENTAL 
Materials and Methods 
PCM and CAF were obtained as gift samples from UNEXO Pharmaceuticals and Avicel PH 102 
and magnesium stearate from Remington Pharmaceuticals, Lahore, Pakistan and were used as 
received. All organic solvents used were of HPLC or analytical grade. A phosphate buffer at pH 
6.8 was prepared by mixing 250 ml of KH2PO4 (0.2 M) and 112 ml of NaOH (0.2 M) with final 
dilution to 1L with distilled water. 
Screening of co- crystals 
Various methods like mechanochemical (dry grinding, liquid assisted grinding (LAG)), solvent 
evaporation (SE) and anti-solvent addition (ASA) were used for the formation of co-crystals of 
PCM with CAF. 
Dry and liquid assisted grinding 
PCM and CAF in three different weight ratios (1:1, 1:2 & 2:1) were co ground in a mortor and 
pestle without and with small amount of liquid (~50 µL for each of 100 mg of PCM and CAF) for 
30 minutes. Solvents used were V/V mixture of methanol & ethanol (1:1&1:2) and pure acetone. 
The powder was collected in tight containers and stored at room temperature. 
Solvent evaporation method 
PCM and CAF in three different weight ratios (1:1, 1:2 & 2:1) were dissolved in a V/V mixture of 
methanol & ethanol (1:1 &1:2), mixture of distilled water & ethanol (1:1, 1:2) and pure acetone 
with aid of slight heating until a clear solution obtained. Each of these solutions was then filtered 
and left for evaporation at room temperature. The solid crystals obtained were collected in a tight 
container for further analysis and stored at room temperature. 
 
Anti-solvent addition 
Excess amount of PCM and CAF (1:1, 1:2 & 2:1 weight ratio) were added to 5 ml of methanol 
and acetone separately to make turbid solutions, stirred for 15 minutes and filtered through 
Whatman filter paper. Distilled water (2 ml) (as an anti-solvent (32)) was added to the filtrate to 
induce precipitation. Samples were then centrifuged at 3000 rpm for 20 minutes to allow solids to 
deposit out. 
Characterization 
The pure drugs and co-crystals prepared by the above methods were investigated by DSC, PXRD, 
ATR-FTIR and Intrinsic dissolution rate (IDR) studies. 
Differential scanning calorimetry (DSC) 
DSC studies were performed using a TA instrument (model Q 600, USA). Samples (2−5 mg) 
contained in alumina pan with an empty pan as a reference were analyzed from room temperature 
(25± 2 °C) to 300 °C with a constant heating rate (10 °C/min) under a nitrogen purge (100 ml/min). 
Powder X-Ray Diffraction (PXRD) 
PXRD patterns were obtained for PCM, CAF and co-crystals synthesized by various methods. 
Powder samples were used as such without any pre treatment. PXRD data were collected on a Pan 
Analytical diffractometer XPERT-PRO (operating at 40 kV, 40 mA), using Cu-Kα radiation (λ = 
1.5418 Å) with a position sensitive detector. Diffraction data were collected in the range 2θ = 5-
30o with a step size of 0.02o.  
ATR-FTIR spectroscopy 
Fourier Transform Infrared (FTIR) spectra were recorded for the PCM, CAF and synthesized co-
crystals using FTIR spectrophotometer (Alpha-P Bruker, Germany) equipped with an ATR unit 
across the range of 4000-400 cm-1.  
Scanning Electron Microscopy (SEM) 
Powder samples were photographed by ZEISS EVO HD 15 scanning electron microscope (Carl 
Zeiss, NTS Ltd. Cambridge, UK) with auto imaging system. The samples were mounted on carbon 
adhesive tape fixed on aluminium stubs (Agar Scientific Ltd., Stansted, UK), flushed with air and 
photographed at the voltage of 2 KV for 25 seconds. 
Drug content analysis 
A stock solution containing 1 mg/mL of pure drug was prepared by dissolving 100 mg of PCM in 
100 mL of phosphate buffer (pH 6.8) using a volumetric flask. The standard stock solution was 
further diluted to obtain a working standard solution of 100 µg/ml. Working standard solution was 
then diluted with phosphate buffer (pH 6.8) to obtain a series of solutions with the concentration 
range of 2-16 µg/ml. A calibration curve for PCM was prepared by measuring the absorbance at 
the λmax of 243 nm. Statistical parameters like slope, intercept and coefficient of correlation were 
determined to model the linearity of absorbance data. 
For drug content analysis, each of the co-crystal samples was accurately weighed (10 mg) and 
dissolved in phosphate buffer pH 6.8 to give final concentration of 10µg/ml. The drug content was 
calculated from the calibration curve.  
Intrinsic dissolution studies 
The intrinsic dissolution rate (IDR) of pure drug, physical mixtures and co-crystals was determined 
by rotating disc method using a constant surface area of 13 mm in diameter. Discs were prepared 
by compressing 300 mg of powder samples by a hydraulic press (Carver, USA) at a pressure of 
~5000 psi for 60-90 seconds. The compacts were coated with hard paraffin leaving a surface 
available for dissolution (33, 34) and then placed to the base of the dissolution vessel.  
The dissolution studies, performed in triplicate, were carried out in phosphate buffer pH 6.8 
(volume: 500 ml, temperature: 37 °C) in a paddle apparatus (Apparatus 2, USP) at a rotation speed 
of 50 rpm. Aliquots (5 ml) were withdrawn at time intervals of 2, 4, 6, 8, 10, 14, 18 and 22 min. 
Samples were filtered through 0.45 μm filters and analyzed at 243 nm. Dissolution medium was 
replenished with the same volume (5ml) of blank (phosphate buffer pH 6.8) in order to maintain 
the sink conditions. IDR was determined by plotting the cumulative amount of drug dissolved per 
surface area (mg/cm2) versus time (min). 
Compressional behavior 
In-die heckle model (35) for powder deformation under pressure (equation 1) was used to study 
the compressional behavior of pure PCM and prepared co-crystals powders. Bulk density of each 
powder was determined by the standard method. Each of the material (300 mg) was individually 
compacted under compressional force between 2 and 14 MPa using a hydraulic press (Carver, 
USA) equipped with flat faced dies 13 mm in diameter. Volume reduction was measured at each 
compaction pressure used. 
dD
dP
= K(1 − D)           Eq. 1 
Where, D is the relative density of the compact at applied pressure P,and the constant K is a 
measure of the plasticity of the compressed material. Integration of equation 1 gives equation 2. 
Ln(1)
(1 − D)
= KP + A              Eq. 2 
A plot was drawn between Ln (1)/1-D and compaction pressure (P) for each powder. A is the 
intercept of the extrapolated linear region of the curve. Mean yield pressure (P y), a measure of 
the material’s resistance for deformation (36), was obtained from the reciprocal of the slope (K) of 
the linear portion of the heckle plot. The higher the value of slope K is, more plastic is the material. 
Preparation of Tablets 
Direct compression method was used to prepare tablets from all co-crystal powders. For this 
purpose co-crystal equivalent to 250 mg of PCM was blended with Avicel PH 102 (20 % of the 
weight of co-crystal) and magnesium stearate (0.5 % of the weight of co-crystal) for about 15 min. 
The mass was then compressed using a hydraulic press fitted with 13 mm diameter die. As pure 
PCM cannot be directly compressed due to poor compressional properties, it was moistened with 
small amount of water and then dried at 50 oC for 10 minutes to induce plasticity and then 
compacted (F1). Tablets from physical mixtures (1:1 & 2:1 by weight ratio of PCM and CAF) 
were prepared following the same procedure. Tablets of pure PCM (F2) (250 mg equivalent) were 
also prepared by the standard wet granulation (WG) method using starch paste (10 % of the weight 
of PCM) as a binder and dry starch as disintegrating agent (10 % of the weight of PCM). 
Evaluation of tablets 
All the prepared tablets were evaluated for hardness, tensile strength, disintegration time and in 
vitro dissolution study. Hardness was determined using Pharmatron Multitest 50H and expressed 
in newton. Tensile strength, σ, in MPa was determined by diametral compression test (37) and 





               Eq. 3 
Where F is the breaking force (N), D is the tablet diameter (m), and T is the thickness of tablet 
(m). Disintegration test was carried out by tablet disintegration test apparatus using distilled water 
at 37 °C.  
In- vitro dissolution study 
Dissolution studies for all prepared tablets were performed using phosphate buffer pH 6.8 (volume: 
900 ml, temperature: 37 °C) as a dissolution medium in a paddle apparatus (Apparatus 2, USP) at 
a rotation speed of 50 rpm. Aliquot (5 ml) was withdrawn at time intervals of 3, 6, 9, 12, 17, 22, 
27 and 32 minutes and replaced with fresh dissolution medium in order to maintain the sink 
conditions. These samples were analyzed for PCM concentration by UV Visible 
spectrophotometer at 243 nm. All the measurements were done in triplicate. Percent drug release 
was determined from the calibration curve (R2 = 0.996). The drug release data was also fitted to 
various kinetic models such as zero order, first order, and Higuchi, Korsmeyer-Peppas and Hixon-
Crowell model using DD solver (38). 
 
 
In-vivo studies in sheep 
An in-vivo study was conducted in sheep model in order assess the pharmacokinetic profiles of 
pure PCM and co-crystals. Sheep model was selected for preclinical evaluation owing to its easy 
handling, more clinically precise and relevant dose alignment. Moreover collection of multiple 
samples per animal is possible without adding risk to animal’s life. The protocols used for this 
studies were approved by animal ethical committee, University College of Pharmacy, University 
of the Punjab, Lahore, Pakistan (ref no. AEC/PUCP/1047A). Three groups (n=6) of sheep were 
orally administered at a dose of 30 mg/kg body weight with pure PCM and equivalent co-crystals 
in gelatin capsules after an overnight fast. Collection of blood samples (3 ml) were undertaken 
from jugular vein in heparinized tubes at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8 and 10 hour intervals post-
dose. From the whole blood, plasma was separated by centrifugation at 3500 rpm for 5 minutes 
and supernatant was collected in Eppendorf tube and stored at -20 oC for further studies.  
For drug analysis, to 1 ml of plasma, 60 µl of 50% perchloric acid was added. This mixture was 
vortexed for 5 minutes and centrifuged at 13500 rpm for 15 minutes. Supernatant was filtered 
using 0.22 µm syringe filter. 50 µl of clear filtrate was injected into the HPLC with a run time of 
10 minutes and drug content was analyzed with a previously reported method (39). The HPLC 
system (Shimadzu 20A, Japan) was equipped with a LC-20AT VP pump, a SIL-20AC HT auto 
sampler, SPD-M20A detector (photodiode array), CTO 20 AC column oven, CBM 20A controller 
unit and a reversed phase symmetry C18 (4.6 x 250 mm, 5-μm particle-size) column. The mobile 
phase was composed of water, methanol, and acetonitrile (80:10:10, v: v: v), filtered through a 
0.45 membrane filter and was delivered at a flow rate of 1 ml/min. The analysis was carried out 
under isocratic conditions maintaining column temperature at 40°C. A photodiode array detector 
set at 245 nm was used for recording chromatograms. Calibration curve (R2 = 0.9974) prepared 
for PCM was based on peak area measurements of standard solutions and spiked plasma samples 
for concentrations of 0.1, 0.5, 1.0, 5.0, 10.0, and 15.0 µg/ml. The limits of detection and 
quantification were 0.03 and 0.1µg/ml respectively. 
The maximum plasma concentration (Cmax) and the time to reach maximum concentration (Tmax) 
were directly obtained from the plasma concentration versus time curves. Pharmacokinetic 
parameters including area under the curve (AUC), area under the first moment curve (AUMC), 
mean residence time (MRT), plasma clearance (CL), apparent volume of distribution (Vd), 
elimination rate constant (Kel) and half life (t1/2) were calculated using non-compartmental analysis 
and PK solver pharmacokinetic programme (40). 
Statistical analysis was conducted by SPSS (IBM SPSS Statistics 22). Statistical data was obtained 
by using one way ANOVA and post hoc comparisons. Statistical significance was considered 
when p < 0.05. 
RESULTS AND DISCUSSION 
Co-crystal screening was carried out by four different methods as described in Table 1. Formation 
of co-crystals were recorded by difference in melting points and PXRD patterns from the 
individual components. PCM-CAF co crystals were successfully prepared by LAG and SE 
methods. In LAG, mixtures of PCM and CAF at weight ratio 1:1 with solvents S1, S2 and S3 were 
resulted in co-crystals (PXRD pattern were different from either of the two starting materials, 
Figure 2). In SE method the solution of PCM and CAF in weight ratio 2:1 using solvent systems 
(S1 and S2) resulted in formation of co-crystals. All the other mixtures/solutions in the screening 
study produced intact crystals of the individual components i.e. PCM and CAF.  
Place table 1 here 
Characterization of newly formed co-crystals was performed using three different techniques 
namely PXRD, DSC and FTIR. PXRD patterns of co-crystals were compared with three 
polymorphs of PCM (denoted as Form I, II and III) and two polymorphs of CAF (denoted as Form 
I and II) in Figure 2. Characteristics peaks of all the polymorphs of PCM and CAF were not 
observed in the patterns of co-crystals. Moreover new peaks were emerged at 2θ value of 8.41o, 
9.06o, 11.39o and 17.66o suggesting the formation of a new phase. The difference in the intensity 
of major peaks in PXRD parents of co-crystals (Figure 2) were due to preferred orientation effect 
(instrument used had a flat sample stage), which may be due to dissimilarity in the habit of particles 
produced by two different methods. A, B and C samples were prepared by the liquid assisted 
grinding (LAG) technique, where grinding resulted in fine powders. However samples D and E 
were prepared by solvent evaporation (SE) technique. Recrystallization in this case resulted in 
small crystallites which create problem in the packing of samples for PXRD analysis. DSC data 
also showed that the resultant powders are new phases as the melting point of co-crystals are 
significantly different from all the polymorphs of starting materials. However, precise 
stoichiometric and structural description of these co-crystals needs further analysis by single 
crystal XRD, which may form the subject of our future studies.. 
DSC curves of newly formed co-crystals and pure PCM (identified as form I) and CAF are shown 
in Figure 3. PCM sample showed a sharp endothermic peak with mid point at 172.37 °C 
representing the melting of PCM form I. Although not evident in this study, paracetamol also exist 
as polymorphs II and III. Form II has melting point at 160 oC, while Form III is most unstable form 
and converts back to form I. CAF thermogram showed two endothermic peaks with mid points at 
160.33 °C and 231.08 °C representing melting of its polymorphic forms i.e. form II and I, 
respectively. DSC curves of co-crystals prepared by the LAG and SE techniques showed 
endothermic peaks with onset temperatures ~ 130 °C and 133 °C respectively (Table 2), which are 
lower than the individual components (PCM and CAF) and all their polymorphs. However sample 
D showed two overlapping peaks which indicate lack of phase purity. With small exceptions, it 
can be presumed that the co-crystals formation resulted in increased entropy evident as a broad 
endothermic peak at temperatures lower than the individual counterparts. 
Figure 4 shows comparison of FTIR spectra of prepared co-crystals with PCM and its physical 
mixture with caffeine in the functional group region of 3000-3400 cm-1. For PCM, peaks for N-H 
amide stretch and phenolic OH stretch were observed at 3323 and 3108 cm-1 respectively. These 
functional groups are involved in the hydrogen bonding of PCM molecules in the crystal structure 
(41). Overall FTIR spectra of co-crystals in the range 400 to 3500 cm-1 show almost similar pattern 
as of PCM, however a shift in the above described bands (i.e. to 3316 cm-1 and 3104 cm-1 
respectively) was observed. This indicates a slight change in the hydrogen bonding pattern of PCM 
in the form of co-crystal. These shifts were not observed for physical mixture.  
Place table 2 here 
Place figure 2, 3 and 4 here  
 
Intrinsic dissolution rate (IDR)  
Intrinsic dissolution rate (IDR) method was employed as it affords advantages over other powder 
dissolution methods because the exposed area of the disk is constant and thus dissolution 
variability can be minimized. Intrinsic dissolution profiles of the prepared co-crystals compared 
with pure drug are shown in Figure 5. IDR of PCM recorded in phosphate buffer pH 6.8 was 5.06 
mg/cm2-min, while for co-crystals A, B, C, D and E was 8.72, 9.53, 12.23, 11.11 and 14.40 
mg/cm2-min respectively. Based on the initial dissolution rate, co-crystals A, B, C, D and E showed 
1.72, 1.88, 2.42, 2.19 and 2.84 fold increase in dissolution rate. In comparison the physical mixture 
showed almost same IDR (5.5 mg/cm2-min) as of the pure drug. This high dissolution rate might 
indicate the stability of prepared co-crystals to prevent dissociation of drug and co-former from 
each other and achieve the solubility and dissolution advantages of co-crystals (42).  
IDR is the dissolution rate that is greatly influenced by the intrinsic factors especially the crystal 
habit and particle size distribution. The variation among the IDR values of co-crystals can be 
explained by the fact that the powders prepared by the two different methods (LAG and SE) have 
different particle size distribution and shapes. This is evident from the SEM images of these 
samples as shown in Figure 6. Mechanochemical method (LAG) produced fine powders with high 
compressibility index (~ 31.12 %). On the other hand the powder samples prepared by SE method 
show larger particles with low compressibility index value of ~ 20.55 %. Owing to this fact more 
compact IDR discs were prepared from LAG samples which resulted in lower values of IDR as 
compared to samples of SE. This is also evident from the higher breaking force (hardness) of the 
tablet formulations prepared from A, B and C samples as compared to D and E samples (Table 3).  
Place figure 5 here 
Place figure 6 here 
Compressional and mechanical properties 
 
Poor compressibility of PCM due to low plasticity is always a problem for the formulation 
scientists. To overcome this problem, PCM is normally tableted by wet granulation (WG) method, 
which is a time consuming and laborious procedure and required a large amount of excipients to 
be added to the formulation. Development of crystal structures, which provide large inter-
particulate bonding area and plasticity, has been proposed as a strategy to improve the tensile 
strength of materials (43). In the present study heckle plots were drawn for pure PCM and co-
crystals powders to assess the plastic behavior induced by co-crystallization (Figure 7). Co-crystals 
showed improved compaction and hence high plasticity. This was shown by low Py (mean yield 
pressure) value for co-crystals as compared to pure drug. Py recorded for PCM was 133.33 MPa. 
The same parameter for formed co-crystals A, B, C, D and E was significantly decreased i-e. 33.03, 
80, 28.65, 33.03 and 47.62 MPa respectively. The ranking of the Py values was 
C<A&D<E<B<PCM (Table 3). These values were calculated from the region of heckle plots 
showing the highest correlation coefficient for linearity of > 0.989 for all the powder samples. The 
yield pressure, Py, is the stress at which particle deformation is initiated reflecting the deformation 
of the particles during compression (44). Difference in compression properties among co-crystals 
produced by LAG and SE is due to dissimilar crystal plasticity which may result from unique 
molecular packing features in the respective crystal lattices. Mechanochemically synthesized co-
crystals are more plastic and have high tensile strength as evident from their low mean yield 
pressure (Py) value (33.03 & 28.65). Previous literature also confirms mechanochemical synthesis 
as an efficient approach to produce plastic and compressible forms of PCM using oxalic acid, 
phenazine, theophylline and naphthalene as coformers (24). 
Place figure 7 here 
Results from the compression data indicate that co-crystals can easily be formulated, by direct 
compression with adequate hardness to the tablet dosage form without adding any binder. The 
tensile strength higher than 3MPa was exhibited by tablets based on co-crystals prepared by LAG 
(FA, FB and FC) while the tablets based on co-crystals prepared by SE were in the vicinity of >1.8 
MPa (Table 3). This suggests that mechanochemical methods of co-crystallization are more 
suitable to improve the pharmacotechnical properties of PCM.  
Place table 3 here 
In- Vitro drug release study of Tablets 
Various tablet formulations prepared from pure drug, physical mixtures and co-crystals were 
subjected to the in vitro dissolution studies for the release of PCM. Direct compression method 
was employed for the co-crystals formulations (FA, FB, FC, FD and FE). However for pure drug, 
both liquid assisted direct compression (F1) and wet granulation method (F2) were used. Figure 8 
shows comparison of dissolution profiles of these formulations. All the co-crystals formulations 
showed 90 - 97 % release within 20 min. This was greater than corresponding physical mixtures 
(55 %), F1 (72 %) and F2 (85 %).  
As already explained before that the LAG method of co-crystallization produce powders with a 
large surface area so mechanochemical synthesis based formulations were expected to give better 
dissolution profiles as compared to SE based formulations. This can also be confirmed by SEM 
results. Furthermore, grinding in the presence of acetone (FC) resulted in even more improved 
dissolution as compared to grinding with V/V mixtures of methanol and ethanol (FD and FE). This 
can be explained by the fact that high solubility of PCM in methanol/ethanol mixture as compare 
to  pure acetone (solubility of PCM in methanol 371, in ethanol 232 and in acetone 111 mg/g of 
the solvent) resulted in solvent assisted recrystallisation as demonstrated by spottiness (loss of 
peak resolution i.e. preferred orientation effect) of PXRD pattern. 
Release kinetics results show that the release of PCM from formulations F1 and F2 followed 
Korsemeyer-Peppas and Hixon- Crowell models, respectively. While dissolution data of the co-
crystal formulations FA &FB followed Korsemeyer-Peppas and formulations FC, FD & FE 
followed Hixon-Crowell model for drug release (Table 4). Moreover all the formulations showed 
non-Fickian (anomalous) drug release (0.45 ≤𝑛≤0.89). 
Place figure 8 here  
Place Table 4 here 
 
In-Vivo performance of PCM and co-crystals 
 
Place figure 9 here 
Powder co-crystal samples from each of the successful method showing higher IDR i.e. C and E 
were selected for oral bioavailability studies. Figure 9 shows the plasma concentration profiles for 
PCM and selected co-crystals. The mean pharmacokinetic metrics calculated from the sheep model 
study data are presented in Table 5. The mean AUC values were 11.22 and 9.36 µgh/ml for co-
crystals C and E, respectively, which were almost two times enhanced that of PCM (5.02 µgh/ml). 
Cmax of C (2.40 µg/ml) and E (1.72 µg/ml) was 2.45 and 1.80 fold that of PCM (0.98 µg/ml) 
without any change in the time for peak concentration. The increase in peak concentration for co-
crystals may be attributed to decreased elimination because of higher accumulation of drug. Mean 
residence time of the co-crystals was observed to be high with low clearance values suggesting 
enhanced absorption window. Co-crystals also showed more than two times enhancement in the 
relative oral bioavailability than the pure PCM. The bioavailability of both co-crystals was 
significantly better than pure drug based on One way ANOVA followed by Tukey’s post hoc test 
(p<0.05). 
Difference in in-vivo behaviour between the co-crystal samples prepared by two methods can be 
attributed to the dissimilarity in the physicochemical properties especially dissolution rate (Figure 
8). Physiological variations among the subjects may also contribute to these small differences. 
However in comparison with each other (C with E and E with C) the pharmacokinetic parameters 
Cmax and AUC were insignificant (p> 0.05).  
Place table 5 here 
CONCLUSION 
PCM is a low solubility compound with poor tabletability. A co-crystal incorporating PCM and 
CAF was successfully developed by liquid assisted grinding and solvent evaporation. Co-crystals 
showed improved IDR and compressional properties. In-Vivo kinetic results from sheep model 
also confirmed a significant increase in the oral bioavailability of PCM. This suggests co-
crystallization a useful technique to improve the compressional, physicochemical and 
pharmacokinetic properties of PCM and proving caffeine a suitable co-former. 
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Table 1. Screening of Co-crystals by using various methods (“+ “ represents formation of co-crystals, characterized 
by DSC and PXRD results, “- “represents re-crystallization of starting material or no crystallization) (co-crystals from 
successful techniques are coded A, B, C, D & E as shown in Table 1) 
Method Used Solvent Used 
Solvent 
ratio 








1 : 1 - 
1 : 2 - 
2 : 1 - 
Liquid assisted 
grinding 
MeOH : EtOH 
1:1 (S1) 
1 : 1 +(A) 
1 : 2 - 
2 : 1 - 
1:2 (S2) 
1 : 1 + (B) 
1 : 2 - 




1 : 1 + (C) 
1 : 2 - 
2 : 1 - 
Solvent 
evaporation 
MeOH : EtOH 
1 : 1 (S1) 
1 : 1 - 
1 : 2 - 
2 : 1 + (D) 
1 : 2 (S2) 
1 : 1 - 
1 : 2 - 




1 : 1 - 
1 : 2 - 
2 : 1 - 
H2O : EtOH 
1 : 1 (S4) 
1 : 1 - 
1 : 2 - 
2 : 1 - 
1 : 2 (S5) 
1 : 1 - 
1 : 2 - 
2 : 1 - 
Anti-Solvent 
Solvents: MeOH & 
Acetone 
Anti- solvent: Water 
 
1 : 1 - 
1 : 2 - 





Table 2: Onset, mid and off set temperatures of DSC thermograms of PCM, CAF and PCM-CAF Co-crystals *(A, B, 
C, D and E are codes given to co-crystals prepared by successful methods as shown in Table 1). 






PCM 165.59 172.37 204.20 
CAF   Form I 
           Form II 
216.99 231.08 247.45 
146.49 160.33 175.91 
A 130.31 141.02 156.57 
B 128.21 140.92 174.19 
C 131.93 142.5 165.87 
D 133.58 160.92 194.16 
E 133.58 148.68 172.51 
 
Table 3. Physical and mechanical properties of tablet formulations prepared from pure PCM (direct compression (F1) 
and wet granulation (F2)) and PCM-CAF Co-crystals.*Mean yield pressure values were derived from Heckle plots 
only from pure PCM and PCM-CAF co-crystals powders. 
Properties F1 F2 FA FB FC FD FE 
Tablet 
diameter(mm) 
13 ± 0.01 13 ± 0.01 13± 0.01 13± 0.01 13± 0.01 13± 0.01 13± 0.01 
Breaking 
force(N) 





1.90 ± 0.01 3.48 ± 0.01 3.67 ± 0.01 3.98 ± 0.01 1.82 ± 0.01 1.88 ± 0.01 
Disintegration 
time(min)                  
1± 0.5 0.67 ± 0.5 8.0 ± 0.5 7.5 ± 0.5 7.5 ± 0.5 5 ± 0.5 5 ± 0.5 
*Mean yield 
pressure(MPa) 




Table 4: Drug release kinetics from various formulations of PCM and PCM-CAF co-crystals 
Release kinetics F1 F2 FA FB FC FD FE 
Zero order  R2 0.9847 0.8559 0.7634 0.7383 0.5443 0.8172 0.7257 
First order R2 0.9821 0.9628 0.9693 0.9575 0.9531 0.9368 0.9688 
Higuchi model R2 0.8926 0.9148 0.9340 0.9053 0.8891 0.8834 0.9327 
Hixon- Crowell 
model 
R2 0.9904 0.9764 0.9775 0.9594 0.9712 0.9517 0.9810 
Korsemeyer-Peppas 
model 
R2 0.9926 0.9421 0.9843 0.9791 0.9230 0.9077 0.9340 
n 0.873 0.659 0.758 0.751 0.549 0.650 0.531 
 
Table 5. Pharmacokinetic parameters of PCM and PCM-CAF Co-crystals in sheep, obtained after single oral 
administration at a dose of 30mg/Kg body weight (n=6). *R.B relative to PCM 
Parameters PCM 
Mean + SD 
C 
Mean + SD 
E 
Mean + SD 
Cmax (μg/ml) 0.98+ 0.18 2.40+ 0.51 1.72+ 0.66 
Tmax (h) 1.67+ 0.25 1.67+ 0.25 1.67+ 0.25 
AUCO-10h (μgh/ml) 5.02+ 1.3 11.22+ 1.67 9.36+ 1.60 
AUCO-∞ (μgh/ml) 5.25+ 0.5 13.01+ 1.22 10.44+ 1.93 
AUMCO-∞ (μgh/ml) 21.86+ 05.19 72.46+ 14.84 53.64+ 10.54 
MRT (h) 3.86+ 0.87 5.52+ 1.07 5.13+ 0.79 
Kel (h-1) 0.33+ 0.15 0.26+0.13 0.27+0.03 
T1/2 (h) 1.36+ 0.41 3.29+ 1.75 2.53+ 0.38 
CL/F (μg/ml)/h 161.48+ 19.01 56.45± 4.48 75.27+ 14.49 
Vd/F (μg/ml) 294.18+ 28.33 264.83+ 26.78 276.72+ 19.19 
*Relative bioavailability 
(R.B) 







Figure 1. Molecular structures of Paracetamol (left) and Caffeine (right) 
Figure 2. PXRD patterns of PCM, CAF and PCM-CAF Co-crystals  
















































Figure 3. DSC thermograms of PCM, CAF and PCM-CAF Co-crystals  
































Figure 4. ATR-FTIR spectra of PCM, PM and PCM-CAF Co-crystals highlighting the N-H amide stretch and 
phenolic OH stretch regions for PCM 
















































































Figure 7. Heckle plots for PCM and PCM-CAF Co-crystals 
 
 
Figure 8. In Vitro drug release comparison of various formulations of PCM, PCM-CAF co-crystals and physical 
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